Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2009
03/12/2009WO2008149230A3 Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
03/12/2009WO2008148892A3 Mc- i r, mc-2 r, and mu opioid receptors modulation
03/12/2009WO2008146167A3 Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
03/12/2009WO2008145524A3 4,4-disubstituted piperidine derivatives
03/12/2009WO2008142267A3 Process for extracting coumarins
03/12/2009WO2008139402A4 A method of inhibiting hiv replication
03/12/2009WO2008139262A8 Oligoribonucleotides and uses thereof
03/12/2009WO2008139235A3 Novel piperazine salts as d3/d2 antagonists
03/12/2009WO2008137778A3 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
03/12/2009WO2008136850A3 Cobalamin conjugates useful as imaging and therapeutic agents
03/12/2009WO2008136018A3 4beta-amin0 podophyllotoxin congeners as potential anticancer agents and a process for the preparation thereof
03/12/2009WO2008135855A3 Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
03/12/2009WO2008135829A3 Nanoparticles comprising cox-2 inhibitors and a non-ionizable polymer
03/12/2009WO2008132600A3 Trpv1 antagonists and uses thereof
03/12/2009WO2008129239A3 Use of agents that inhibit homologous recombination for the treatment of cancer
03/12/2009WO2008125945A3 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
03/12/2009WO2008125116A3 Upar inhibition
03/12/2009WO2008124151A3 Use of creatine compounds for the treatment of eye disorders
03/12/2009WO2008124088A3 Compositions and methods for the treatment of heart failure
03/12/2009WO2008117018A3 A tablet having improved stability with at least two actives
03/12/2009WO2008116185A3 Substituted pyrimidines as adenosine receptor antagonists
03/12/2009WO2008113557A3 Anti-infective agents
03/12/2009WO2008106228A3 Methods and compositions for normalizing meibomian gland secretions
03/12/2009WO2008094737A3 Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
03/12/2009WO2008092143A3 Rnai-mediated inhibition of aquaporin 4 for treatment of ocular neovascularization
03/12/2009WO2008092046A3 Amorphous oxcarbazepine and the production thereof
03/12/2009WO2008079836A4 Macrocyclic factor viia inhibitors useful as anticoagulants
03/12/2009WO2008073444A3 Phou (perf), a persistence switch involved in persister formation as a drug target for persister bacteria
03/12/2009WO2008059052A9 Improved methods of using phosphoantigen for the treatment of cancer
03/12/2009WO2008055141A3 Liquid formulations of phospholipase enzyme inhibitors
03/12/2009WO2008041116A3 Formulations of active principles incorporated in slns suitable for transdermal administration
03/12/2009WO2008035305A8 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
03/12/2009WO2008021389A8 Using pi3k and mek modulators in treatments of cancer
03/12/2009WO2008014219A8 Thiozolidinedione derivatives as p13 kinase inhibitors
03/12/2009WO2008013807A9 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer
03/12/2009WO2007134107A3 Cold menthol receptor-1 antagonists
03/12/2009WO2007129274A9 Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350.
03/12/2009WO2007092681A3 Piperidinyl derivatives as modulators of chemokine receptor activity
03/12/2009WO2007016134A9 BICYCLIC 6-ALKYLIDENE-PENEM B-LACTAMASE INHIBITORS AND β-LACTAM ANTIBIOTIC COMBINATION: A BROAD SPECTRUM ANTIBIOTIC
03/12/2009WO2006122806A3 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
03/12/2009WO2005055975A3 Uv-stable semi-solid transdermal systems comprising a photosensitive active ingredient and a uv absorber
03/12/2009WO2005046656A3 Use of 5 - chloro-1- (2, 6 - dichloro - 4 - trifluoromethylphenyl) - 4 - (4, 5 - dicyano - 1h - imidazol - 2yl) -3 - methyl - 1h - pyrazole in systemic control of acarid infestation on animals
03/12/2009US20090069789 Methods and devices for local therapeutic agent delivery to heart valves
03/12/2009US20090069623 Methods and compositions for treatment or prevention of radiation-induced fibrosis
03/12/2009US20090069565 New indole derivatives as factor xa inhibitors
03/12/2009US20090069564 Methods and Compositions for Selectin Inhibition
03/12/2009US20090069445 Propofol-containing fat emulsions
03/12/2009US20090069444 Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
03/12/2009US20090069443 Sedative Effect-Imparting Agent And Sedative Perfume Composition Containing The Same
03/12/2009US20090069442 Therapeutic Agent for Sensory Abnormality
03/12/2009US20090069441 Motuporamine Mimic Agents
03/12/2009US20090069440 Deuterium-enriched atomoxetine
03/12/2009US20090069439 Use of pargyline for the treatment of hair folliclies
03/12/2009US20090069437 Compositions for Oral Transmucosal Delivery of Metformin
03/12/2009US20090069436 Antimicrobial skin composition comprising a biguanide or a quaternium compound
03/12/2009US20090069435 Bridged polycyclic compound based compositions for topical applications for pets
03/12/2009US20090069434 Cystalline form VI of agomelatine, a process for its preparation and pharmaceutical compositions containing it
03/12/2009US20090069433 Nasal rinse additive
03/12/2009US20090069432 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
03/12/2009US20090069431 Deuterium-enriched milnacipran
03/12/2009US20090069430 Dibenzene derivatives as calcium channel blockers
03/12/2009US20090069429 Compositions Comprising Alpha-Ketoglutarate and Their Use for Modulating Muscle Performance
03/12/2009US20090069428 Catalytic antioxidants and methods of use
03/12/2009US20090069427 Alpha-2-delta ligands for non-restorative sleep
03/12/2009US20090069426 Methods For Reducing The Amount Of A Proinflammatory Substance In Animal Tissue Or Body Fluid
03/12/2009US20090069425 Active composition for treatment or prevention of problems related to a disturbance of the biological clock
03/12/2009US20090069424 TGF-alpha expression inhibitors
03/12/2009US20090069423 Germinating sunflower seeds in sucrose and oxygen controlled environment to enhance production of eicosapentaenoyl-L-carnitine, docosahexaenyl-L-carnitine; treatment of Alzheimer's, geriatric depression and schizophrenia
03/12/2009US20090069422 containing ethyl pyruvate and a therapeutically effective amount of at least one alpha -hydroxy branched-chain amino acid metabolite selected from alpha-hydroxyisocaproic acid, alpha -hydroxy- beta -methylvaleric acid, and alpha -hydroxy-isovaleric acid; time-release agents; nutritional supplement
03/12/2009US20090069421 Crystal polymorph of hydroxynorephedrin derivative hydrochloride
03/12/2009US20090069420 Small molecule inhibitors of STAT3 with anti-tumor activity
03/12/2009US20090069419 Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
03/12/2009US20090069418 Compositions and Methods for the Treatment of Disorders Associated with Aberrant Vasodilation
03/12/2009US20090069417 Carotenoid oxidation products as chemopreventive and chemotherapeutic agents
03/12/2009US20090069416 Cosmetic Composition for Skin and Wrinkle Improver
03/12/2009US20090069415 Deuterium-enriched nebivolol
03/12/2009US20090069414 Epicatechin and vasodilation
03/12/2009US20090069413 Deuterium-enriched olopatadine
03/12/2009US20090069412 Deuterium-enriched sugammadex
03/12/2009US20090069411 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
03/12/2009US20090069410 Deuterium-enriched paclitaxel
03/12/2009US20090069409 Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
03/12/2009US20090069408 Tricyclic compounds useful in treating iron disorders
03/12/2009US20090069406 Analogs of tetramic acid
03/12/2009US20090069405 Treatment of cns and pain disorders
03/12/2009US20090069404 Atrial fibrillation
03/12/2009US20090069403 Composition and method for reducing allergen
03/12/2009US20090069402 Deuterium-enriched atrasentan
03/12/2009US20090069401 Marine actinomycete taxon for drug and fermentation product discovery
03/12/2009US20090069400 Indole Sulfonamide Modulators of Progesterone Receptors
03/12/2009US20090069399 Deuterium-enriched frovatriptan
03/12/2009US20090069397 Deuterium-enriched olmesartan
03/12/2009US20090069396 Polyene Oxazoles and Processes for Their Preparation
03/12/2009US20090069395 Deuterium-enriched famotidine
03/12/2009US20090069394 Cancer treatment with epothilones
03/12/2009US20090069393 Parenteral formulation for epothilone analogs
03/12/2009US20090069391 such as N-hydroxy-6-{1-[(4-methoxybenzyl)amino]-2-[(4-methoxyphenyl)amino]-2-oxoethyl}-1-benzothiophene-2-carboxamide, used to treat cancer, tumors, neurodegenerative, autoimmune, allergic and inflammatory diseases, and as histone deacetylase inhibitors
03/12/2009US20090069390 Lennox-Gastaut syndrome and/or seizure disorders
03/12/2009US20090069389 Novel controlled release-niacin formulation
03/12/2009US20090069388 Deuterium-enriched sorafenib